Biotech & MedTech News
-
Zentek Receives ISO 13485:2016 Certification
May 18, 2023 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSXV:ZEN), a graphene technology development and commercialization company…
-
Zentek Provides Update on Icephobic Technology for Drones
May 4, 2023 (Source) – Further to its press release dated September 19, 2022, Zentek Ltd. (“Zentek” or…
-
Zentek Provides Review of Albany Graphite
May 03, 2023 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (NASDAQ ZTEK)(TSXV: ZEN), a graphene technology development and…
-
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
May 02, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Zentek Announces Agreement to Transfer Albany Graphite Project to Subsidiary and Intention of Albany Graphite Corp. to Complete a Private Placement Financing
April 25, 2023 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSXV:ZEN), a graphene technology development and commercialization company…
-
Zentek Files Patent Applications for ZenGUARD(TM) in Multiple New Jurisdictions
April 05, 2023 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (NASDAQ:ZTEK)(TSX-V:ZEN), a graphene technology development and commercialization company,…
-
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates
April 03, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased…
-
Zentek Engages Arka BRENStech Pvt Ltd to Develop Opportunities in India
March 30, 2023 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (NASDAQ:ZTEK)(TSXV: ZEN), an intellectual property development and commercialization…
-
Hemostemix Engages Montreal’s RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
March 29, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Cardiol Therapeutics Announces Year-End 2022 Update on Operations
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™…
